Downtrend on the daily chart: below its 50- and 200-day averages · 50-day below the 200-day · SuperTrend down since Jun 10 · below the Ichimoku cloud · RSI 26 (oversold) · MACD below its signal · 4% above its 52-week low
| Investor | Value | Of portfolio | Shares | Change | Quarter |
|---|---|---|---|---|---|
| Renaissance Technologies | $111.4K | 0.00% | 25.50K | New | Q2 2026 |
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a NEUP trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Oct 20, 2025 | Lynx1 Capital Management LpBeneficial Owner of more than 10% of a Class of Security | Purchase at price 5.14 per share. | 639.1K | $3.28M |
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 3.6 | 3.2 | -1.9 | 29.5 | 0.8 | -17.7 | -11.2 | -3.1 | -5.3 | -7.1 | −14.7% | ||
| 2025 | 54.5 | -1.9 | 10.8 | -12.0 | 31.1 | 6.8 | 14.2 | 39.7 | 4.1 | -61.4 | -0.7 | -14.2 | +13.1% |
| 2024 | -34.7 | 28.2 | -16.9 | -7.8 | -11.6 | -8.7 | -1.8 | -14.6 | -31.7 | -54.7 | 50.8 | -4.7 | −80.7% |
| 2023 | -14.0 | -25.0 | -13.3 | -13.5 | -1.3 | -0.9 | -25.5 | 9.8 | 50.0 | -8.9 | -46.3 | 12.1 | −68.2% |
| 2022 | -10.5 | -9.2 | -16.7 | -8.2 | -3.1 | -7.5 | -6.3 | 17.6 | -18.6 | 31.7 | -15.2 | -33.6 | −62.9% |
| 2021 | — |
No analyst coverage for this instrument.
Neuphoria Therapeutics Inc., a clinical stage biopharmaceutical company, develops novel allosteric ion channel modulators for patients with serious central nervous system disorders in Australia. Its lead product candidate is BNC210, an oral, proprietary, selective negative allosteric modulator of the alpha7 nicotinic acetylcholine receptor for post-traumatic stress disorder. The company also develops Merck alpha7 positive allosteric modulators. It has a research collaboration and license agreement with Merck & Co., Inc. to develop alpha7 receptor positive allosteric modulators targeting cognitive dysfunction associated with Alzheimer's disease and other central nervous system conditions. The company was formerly known as Bionomics Limited and changed its name to Neuphoria Therapeutics Inc. in December 2024. Neuphoria Therapeutics Inc. was incorporated in 1996 and is based in Millis, Massachusetts.